< Prescribing
NovoLog® offers broad formulary access1
Your patients can count on NovoLog® (insulin aspart [rDNA origin] injection) managed care access. NovoLog® FlexPen® and vials are on Tier 2, with the lowest branded copay, for more than 95% of managed care patients nationwide.1*
NovoLog® is covered for more than 95% of managed care patients nationwide.1*
Lowest branded co-pay for your Medicare Part D patients1
NovoLog® formulary status at top commercial health care and Medicare Part D plans is comparable to regular human insulin.†
* Managed care plans only. Does not include Medicaid and Medicaid Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status is subject to change.
† Regular human insulin is not a generic. No generic insulins are available in the United States.
Indications and Usage NovoLog® (insulin aspart [rDNA origin] injection) is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.
Important Safety Information NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. See More
More units. Same co-pay.
One box of NovoLog® FlexPen® provides 50% more insulin than a vial for the same co-pay on most managed care plans
9 out of 10 physicians say it is important to minimize patients’ out-of-pocket costs when prescribing2
Indications and Usage
NovoLog® (insulin aspart [rDNA origin] injection) is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.
Important Safety Information
NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.
NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.
Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.
Needles and NovoLog® FlexPen® must not be shared.
NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.
Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.
Insulin lispro is not approved for use in children by subcutaneous continuous infusion via external insulin pump.
An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes.
All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure, This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy.
Please click here for Prescribing Information.
